Market Closed -
Nasdaq
04:00:00 2024-05-14 pm EDT
5-day change
1st Jan Change
1.495
USD
-1.64%
-3.55%
-18.75%
Presentation Operator MessageOperator (Operator)Good day, and thank you for standing by. Welco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target
May. 13
MT
Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Earnings Flash (BDSX) BIODESIX Reports Q1 Revenue $14.8M, vs. Street Est of $14.2M
May. 08
MT
Biodesix, Inc. announced that it has received $34.999422 million in funding
Apr. 08
CI
Top Midday Decliners
Apr. 05
MT
Biodesix, Inc. announced that it expects to receive $34.999422 million in funding
Apr. 04
CI
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center
Mar. 25
MT
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center
Mar. 25
CI
Transcript : Biodesix, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Mar. 01
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 01
CI
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 01
CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2024
Mar. 01
CI
Earnings Flash (BDSX) BIODESIX Posts Q4 Revenue $14.7M
Mar. 01
MT
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method
Nov. 14
CI
Transcript : Biodesix, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Earnings Flash (BDSX) BIODESIX Reports Q3 Revenue $13.5M, vs. Street Est of $14.4M
Nov. 07
MT
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2023
Nov. 07
CI
Transcript : Biodesix, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:15 PM
23-09-12
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
23-09-07
CI
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
23-08-22
CI
Transcript : Biodesix, Inc., Q2 2023 Earnings Call, Aug 07, 2023
23-08-07
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-07
CI
Earnings Flash (BDSX) BIODESIX Reports Q2 Revenue $11.9M, vs. Street Est of $11.7M
23-08-07
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
More about the company
Last Close Price
1.495
USD
Average target price
3.25
USD
Spread / Average Target
+117.39%
Consensus
1st Jan change
Capi.
-18.75% 173M -15.74% 8.58B +63.16% 4.12B -3.34% 2.48B -9.81% 2.44B -43.01% 2.29B -4.82% 2B -18.74% 1.53B -40.24% 1.21B +9.42% 1.12B
Medical & Diagnostic Laboratories
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1